We are pioneering a new therapeutic approach to treat debilitating ear, nose and throat (ENT) diseases that impact the lives of millions of people.
Our first product candidate targets chronic rhinosinusitis (CRS), which affects about 14 million in the U.S.
Jul 07, 2020 Lyra Therapeutics Announces Robert Richard, Ph.D., as Senior Vice President of Research and Development
Jun 25, 2020 Lyra Therapeutics Set to Join the Russell 2000® Index and Russell 3000® Index
